Comparison of anti-CD20 and anti-CD45 antibodies for conventional and pretargeted radioimmunotherapy of B-cell lymphomas

Blood

Volumn 101, Issue 6, 2003, Pages 2340-2348

  Pagel, John M ^a   Hedin, Nathan ^b   Subbiah, Krishnan ^b   Meyer, Damon ^b   Mallet, Robert ^b   Axworthy, Donald ^b   Theodore, Louis J ^b   Wilbur, D Scott ^b   Matthews, Dana C ^b   Press, Oliver W ^b  

^a Fred Hutchinson Cancer Research Center   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; ANTIBODY CONJUGATE; BIOTIN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CD20; MONOCLONAL ANTIBODY CD45; RADIOACTIVE IODINE; STREPTAVIDIN; UNCLASSIFIED DRUG; YTTRIUM 90;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; B CELL LYMPHOMA; CANCER RECURRENCE; CANCER REGRESSION; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; HUMAN CELL; MOUSE; NONHODGKIN LYMPHOMA; NONHUMAN; PRIORITY JOURNAL; RADIATION ABSORPTION; RADIATION DOSE DISTRIBUTION; RADIOIMMUNOTHERAPY; RADIOIODINATION; TREATMENT OUTCOME; TUMOR XENOGRAFT;

EID: 0037443452     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2002-03-0874     Document Type: Article

References (43)

1. Greenlee RT, Hill-Harmon MB, Murray T, Thun M. Cancer Statistics, 2001. CA Cancer J Clin. 2001; 51:15-36.
2. Press OW, Eary JF, Appelbaum FR, et al. Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support. N Engl J Med. 1993;329:1219-1224.
3. Press OW, Eary JF, Appelbaum FR, et al. Phase II trial of 131I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas. Lancet. 1995;346:336-340.
4. Knox SJ, Goris mL, Trisler K, et al. Yttrium-90-labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma. Clin Cancer Res. 1996;2:457-470.
5. Kaminski MS, Estes J, Zasadny KR, et al. Radioimmunotherapy with iodine (131)1 tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience. Blood. 2000;96:1259-1266.
6. Kaminski M, Zelenetz A, Press O, et al. Multicenter phase III study of iodine-131-tositumomab (anti-B1 antibody) for chemotherapy-refractory low grade or transformed low grade non-Hodgkin's lymphoma [abstract]. Blood. 1998;92: 3169.
7. Witzig TE, White CA, Wiseman GA, et al. Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin's lymphoma. J Clin Oncol. 1999;17:3793-3803.
8. Liu SY, Eary JF, Petersdorf SH, et al. Follow-up of relapsed B-cell lymphoma patients treated with iodine-131-labeled anti-CD20 antibody and autologous stem-cell rescue. J Clin Oncol. 1998;16: 3270-3278.
9. Press OW, Eary JF, Gooley T, et al. A phase I/II trial of iodine-131-tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B cell lymphomas. Blood. 2001;96:2934-2942.
10. Fowler JF, Denekamp F. Radiation effects in normal tissues. In: Becker FF, ed. Cancer 6: A Comprehensive Treatise, Radiotherapy Surgery and Immunotherapy. New York, NY: Plenum Press; 1977;139-179.
11. Press OW, Rasey J. Principles of radioimmunotherapy for hematologists and oncologists. Semin Oncol. 2000;27(suppl 12):62-73.
12. Paganelli G, Malcovati M, Fazio F. Monoclonal antibody pretargetting techniques for tumour localization: the avidin-biotin system: International Workshop on Techniques for Amplification of Tumour Targetting. Nucl Med Commun. 1991;12: 211-234.
13. Paganelli G, Pervez S, Siccardi AG, et al. Intraperitoneal radio-localization of tumors pretargeted by biotinylated monoclonal antibodies. Int J Cancer. 1990;45:1184-1189.
14. Paganelli G, Magnani P, Zito F, et al. Three-step monoclonal antibody tumor targeting in carcinoembryonic antigen-positive patients. Cancer Res, 1991;51:5960-5966.
15. Yao Z, Zhang M, Kobayashi H, et al. Improved targeting of radiolabeled streptavidin in tumors pretargeted with biotinylated monoclonal antibodies through an avidin chase. J Nucl Med. 1995; 36:837-841.
16. Saga T, Weinstein JN, Jeong JM, et al. Two-step targeting of experimental lung metastases with biotinylated antibody and radiolabeled streptavidin. Cancer Res. 1994;54:2160-2165.
17. Axworthy DB, Fritzberg AR, Hylarides MD, et al. Preclinical evaluation of an anti-tumor monoclonal antibody/streptavidin conjugate for pretargeted Y-90 radioimmunotherapy in a mouse xenograft model. J Immunother. 1994;16:158.
18. Weiden PL, Breltz HB. Pretargeted radioimmunotherapy (PRIT) for treatment of non-Hodgkin's lymphoma (NHL). Crit Rev Oncol Hematol. 2001; 40(1):37-51.
19. Wilbur DS, Hamlin DK, Vessella RL, et al. Antibody fragments in tumor pretargeting: evaluation of biotinylated Fab' colocalization with recombinant streptavidin and avidin. Bioconjug Chem. 1996;7:689-702.
20. Sung C, van Osdol WW, Saga T, Neumann RD, Dedrick RL, Weinstein JN. Streptavidin distribution in metastatic tumors pretargeted with a biotinylated monoclonal antibody: theoretical and experimental pharmacokinetics. Cancer Res. 1994;54:2166-2175.
21. Breitz HB, Weiden PL, Beaumier PL, et al. Clinical optimization of pretargeted radioimmunotherapy with antibody-streptavidin conjugate and 90Y-DOTA-biotin. J Nucl Med. 2000;41(1):131-140.
22. Weiden PL, Breitz HB, Press O, et al. Pretargeted radioimmunotherapy (PRIT) for treatment of non-Hodgkin's lymphoma (NHL): initial phase I/II study results. Cancer Biother Radiopharm. 2000; 15:15-29.
23. Knox SJ, Goris ML, Tempero M, et al. Phase II trial of yttrium-90-DOTA-biotin pretargeted by NR-LU-10 antibody/streptavidin in patients with metastatic colon cancer. Clin Cancer Res. 2000;6:406-414.
24. Press OW, Corcoran M, Subbiah K, et al. A comparative evaluation of conventional and pretargeted radioimmunotherapy of CD20-expressing lymphoma xenografts. Blood. 2001;98:2535-2543.
25. Axworthy DB, Reno JM, Hylarides MD, et al. Cure of human carcinoma xenografts by a single dose of pretargeted yttrium-90 with negligible toxicity. Proc Natl Acad Sci U S A. 2000;97:1802-1807.
26. Theodore LJ, Axworthy DB, Reno JM, inventors. Small molecular weight ligand hexose containing clearing agents. US Patent 6 075 010. June 3, 2000.
27. Theodore LJ, Axworthy DB, inventors. Cluster clearing agents. US Patent 6 172 045. January 9, 2001.
28. Press OW, Howell-Clark J, Anderson S, Bernstein I. Retention of B-cell-specific monoclonal antibodies by human lymphoma cells. Blood. 1994;83:1390-1397.
29. Omary MB, Trowbridge IS, Battifora HA. Human homologue of murine T200 glycoprotein. J Exp Med. 1980;152:842-852.
30. Andres TL, Kadin ME. Immunologic markers in the differential diagnosis of small round cell tumors from lymphocytic lymphoma and leukemia. Am J Clin Pathol. 1983;79:546-552.
31. Press OW, Farr AG, Borroz KI, Anderson SK, Martin PJ. Endocytosis and degradation of monoclonal antibodies targeting human B-cell malignancies. Cancer Res. 1989;49:4906-4912.
32. Michel RB, Mattes MJ. Intracellular accumulation of the anti-CD20 antibody 1F5 in B-lymphoma cells. Clin Cancer Res. 2002;8:2701-2713.
33. Matthews DC, Appelbaum FR, Eary JF, et al. Phase I study of (131)1-anti-CD45 antibody plus cyclophosphamide and total body irradiation for advanced acute leukemia and myelodysplastic syndrome. Blood. 1999;94:1237-1247.
34. 131I anti-CD45 antibody plus busulfan/cyclophosphamide in matched transplants for AML in first remission [abstract]. Blood. 1996;88(suppl):142.
35. 186Re radioimmunotherapy of small cell lung carcinoma xenografts in nude mice. Cancer Res. 1991;51:676-681.
36. Hylarides MD, Mallet R, Meyer DL. A robust method for the preparation and purification of antibody/streptavidin conjugates. Bioconj Chem. 2001;12:421-427.
37. 131I-anti-CD45 antibody in congenic and H2-mismatched murine transplant models. Blood. 1999;93:737-745.
38. Schultz J, Lin Y, Sanderson J, et al. Atetravalent single-chain antibody-streptavidin fusion protein for pretargeted lymphoma therapy. Cancer Res. 2000;60:6663-6669.
39. Axworthy DB, Theodore LJ, Gustavson LM, Reno JM, inventors. Biotinidase resistant biotin-DOTA conjugates. US Patent 5 955 605. September 21, 1999.
40. Buchsbaum DJ, Langmuir VK, Wessels BW. Experimental radioimmunotherapy. Med Phys. 1993;20:551-567.
41. 90yttrium-DOTA-biotin [abstract]. Proc ASCO. 2002;21:9.
42. Shawler DL, Bartholomew RM, Smith LM, Dillman RO. Human immune response to multiple injections of murine monoclonal IgG. J Immunol. 1985;135:1530-1535.
43. Schroff RW, Foon KA, Beatty SM, Oldham RK, Morgan AC Jr. Human anti-murine immunoglobulin responses in patients receiving monoclonal antibody therapy. Cancer Res. 1985;45:879-885.